Pan-squamous genomic profiling stratified by anatomic tumor site and viral association

M. Montesion
*Foundation Medicine, Inc.*

C. H. Chung
*Lee Moffitt Cancer Center and Research Institute*

E. S. Sokol
*Foundation Medicine, Inc.*

S. A. Khan
*University of Texas Southwestern Medical Center*

H. Kang
*Johns Hopkins University School of Medicine*

Follow this and additional works at: [https://jdc.jefferson.edu/medoncfp](https://jdc.jefferson.edu/medoncfp)

Let us know how access to this document benefits you

*See next page for additional authors*

**Recommended Citation**

https://jdc.jefferson.edu/medoncfp/115

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning (CTL)](https://ctl.jefferson.edu). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Pan-squamous genomic profiling stratified by anatomic tumor site and viral association

1Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, MA, USA, 2Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 3Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA, 4Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 5Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA, 6Clinical Development, Foundation Medicine, Inc., Cambridge, MA, USA, 7Pathology, Foundation Medicine Inc., Cambridge, MA, USA

Background: Squamous cell carcinomas (SCC) have diverse anatomic etiologies but may share common genomic biomarkers. We profiled 7,871 unique SCCs across nine anatomic sites to investigate commonality in genomic alterations (GA), tumor mutational burden (TMB), human papillomavirus (HPV) association, and mutational signatures.

Methods: Tissue from over 8,100 unique SCC samples originating from nine anatomic sites (anogenital (anus, cervix, penis, vagina, vulva), esophagus, head and neck, lung, and skin) were sequenced by hybrid-capture-based comprehensive genomic profiling to evaluate GA and TMB. About 3% of non-cutaneous SCC samples had UV signatures, indicative of potential primary site misdiagnoses, and were filtered from the analysis. Detection of HPV, including high-risk strains 16, 18, 31, 33, and 45, was implemented through de novo assembly of non-human sequencing reads and BLASTn comparison against all viral nucleotide sequences in the NCBI database.

Results: The proportion of HPV+ patients by anatomic site varied, with the highest being anal (91%) and cervical (83%). The mutational landscape of each cohort was similar, regardless of anatomic origin, but clustered based on HPV status. The largest differences in GA frequency as stratified by HPV- vs. HPV+ were TP53 (87% vs. 12%), CDKN2A (45% vs. 6%), and PIK3CA (22% vs. 33%). The median TMB in cases originating from HPV-associated sites was similar, regardless of HPV status. Higher median TMB was observed in lung and skin cases, which exhibited significant enrichment of mutational signatures indicative of tobacco- and UV-induced DNA damage, respectively.

Conclusions: HPV+ and HPV- SCC populations have distinct genomic profiles and, for the latter, anatomic site is correlated with TMB distribution, secondary to associated carcinogen exposure. As such, biomarkers such as TMB and UV signature can provide unexpected insight into site of origin misdiagnoses and may correlate with benefit from immune checkpoint inhibitors.

<table>
<thead>
<tr>
<th>Tumor Site</th>
<th>% HPV+</th>
<th>Median TMB (Interquartile Range)</th>
<th>% TMB &gt; 10</th>
<th>% TMB &gt; 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anogenital (n = 1213)</td>
<td>76</td>
<td>5 (6)</td>
<td>17</td>
<td>5</td>
</tr>
<tr>
<td>Head and Neck (n = 1843)</td>
<td>36</td>
<td>4 (5)</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Esophageal (n = 416)</td>
<td>6</td>
<td>5 (4)</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>Lung (n = 3977)</td>
<td>5</td>
<td>9 (8)</td>
<td>43</td>
<td>9</td>
</tr>
<tr>
<td>Skin (n = 422)</td>
<td>8</td>
<td>40 (69)</td>
<td>68</td>
<td>62</td>
</tr>
</tbody>
</table>

Legal entity responsible for the study: Foundation Medicine, Inc.

Funding: Foundation Medicine, Inc.

Disclosure: M. Montesion, E.S. Sokol: Employee: Foundation Medicine, Inc. L.A. Albacker, G.M. Frampton, V.A. Miller, J.S. Ross, S.M. Ali: Employee and stock ownership: Foundation Medicine, Inc. All other authors have declared no conflicts of interest.